{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "REPL",
  "name": "Replimune Group, Inc.",
  "url": "https://frontierpicks.com/dossiers/REPL/",
  "json_url": "https://frontierpicks.com/dossiers/REPL.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Replimune's melanoma drug TUDRIQEV, approved on 6 August 2026 and first delivered to patients on 6 October 2026, has lifted the shares to a 52-week high on early launch signs. The fiscal third-quarter report, expected around February 2027, shows whether first sales support the move.",
  "invalidation_trigger": "A daily close below $14.00, which would give back most of the rally that followed the 2026-10-28 quarterly report. Fiscal third-quarter TUDRIQEV revenue showing that prescribing has stalled would also break the case.",
  "catalyst_date": null,
  "pick": {
    "id": "P-2026-10-30-REPL",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-30",
    "open_close": 17.61,
    "kill_level": 14,
    "kill_basis": "daily",
    "horizon_end": "2027-02-02",
    "last_date": "2026-10-30",
    "last_close": 17.61,
    "return_pct": 0,
    "spy_return_pct": 0,
    "excess_pp": 0,
    "kill_distance_pct": 25.785714285714278,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Replimune's fiscal year ends March 31, so the quarter ended September 30, 2026 is its fiscal second quarter of 2027.",
    "TUDRIQEV holds accelerated approval; keeping it depends on confirming clinical benefit in the Phase 3 IGNYTE-3 trial.",
    "The company describes its cash runway as greater than twelve months from the date of its financial statements, the minimum period the going-concern accounting test requires."
  ],
  "body_markdown": "## Current Thesis\nReplimune is now a commercial company. Its melanoma drug TUDRIQEV won accelerated approval on 2026-08-06 and reached its first patients on 2026-10-06, and early signs from the launch have lifted the shares to a 52-week high. The case depends on how fast doctors take up the drug. The fiscal third-quarter report, expected around February 2027, will give the first revenue figure and settle it.\n\nReplimune reported fiscal second-quarter 2027 results on 2026-10-28, for the quarter ended 2026-09-30. The net loss was $57.1 million, or $0.54 per share, against a consensus estimate of a $0.77 loss (Benzinga). Cash was $307.8 million, helped by an August stock offering that raised about $141.0 million net. The shares rose 18% on the day of the report (ad-hoc-news) and closed at $17.39 on 2026-10-29, the 52-week high in adjusted daily closes.\n\nThe narrative is accelerating: new facts arrived in quick succession. The drug went on sale in the US on 2026-10-01, the earnings beat came on 2026-10-28, and Leerink Partners raised its target to $31 on 2026-10-29. The Oncology & immunology group, whose peers include GMAB, KNSA and HALO, has also been heating up again since late October.\n\n## Bull Case\n- The label covers advanced cutaneous melanoma that has progressed on anti-PD-1 therapy. Approval followed two complete response letters and a 10–3 advisory committee vote in favour on 2026-07-30 (AJMC).\n- **Responses in the trial were durable.** In the 140-patient IGNYTE trial, 32.9% of patients had a confirmed response, and responses lasted a median of 33.7 months (AJMC).\n- **The launch is opening accounts quickly.** On 2026-10-28 the company reported more than 15 institutions prescribing and contact with more than 70% of its initial 200 priority accounts. It also cited a category 2A listing in the National Comprehensive Cancer Network (NCCN) guidelines and published payer policies that cover use within the label.\n- **The drug carries a high price.** The list price is $450,000 per course of therapy (2026-10-28 earnings call). The company holds more than one year of inventory, made in its own facility.\n- Research and development fell to $34.4 million from $57.9 million (2026-10-28 results release).\n- **A brokerage raised its target.** On 2026-10-29 Leerink Partners kept its Outperform rating and raised its price target to $31 (Benzinga).\n\n## Bear Case\n- **There is no revenue yet.** Product revenue was zero in the quarter ended 2026-09-30, because the first delivery came on 2026-10-06. The company gives no revenue guidance.\n- **The approval is conditional.** Keeping the approval depends on confirming clinical benefit in IGNYTE-3, a Phase 3 trial whose primary goal is overall survival. As of 2026-10-28 the trial was still enrolling, and the company has not given its size or a readout date.\n- **Funding has come from new shares.** The quarter's weighted average share count was 105.2 million, up from 91.9 million a year earlier. Replimune raised about $141.0 million net in August 2026 and drew $15.0 million from a fourth tranche of its loan facility in September 2026.\n- **The cash runway is short.** The company says its cash will fund operations for \"greater than twelve months\" from the date of its financial statements (2026-10-28). That is the minimum period the accounting test for a going-concern warning requires.\n- **The FDA was sceptical until late.** FDA reviewers reportedly gave a negative assessment ahead of the 2026-07-30 advisory panel (AJMC). Any further regulatory friction would fall on a stock that has already priced in a working launch.\n\n## Setup & Price Structure\nThe shares closed at $17.39 on 2026-10-29. That was the 52-week high in split- and dividend-adjusted daily closes. They are up 46.0% over three months.\n\nThe 14-day relative strength index (RSI), a momentum gauge, stood at 68.3 on 2026-10-29. Many technical analysts treat readings above 70 as overbought, so the gauge is close to that line. Much of the recent gain came in one session, the 18% rise on 2026-10-28.\n\nThe visible signs of crowding are a fast run to a new high and the August 2026 share offering, sold as the stock rose after approval. A daily close below $14.00 would give back most of the rally that followed the report.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-30 to 2026-11-29:** Company releases show no scheduled company event in this window. Any update on the launch would have to come from investor-conference appearances, and none has been dated.\n- **~2027-02-11, est.:** Fiscal third-quarter 2027 report, covering the quarter to 2026-12-31. It will carry the first TUDRIQEV sales figure, which is the number the case turns on.\n\n## Elapsed catalysts\n\n- **IGNYTE-3 and RP2 REVEAL (uveal melanoma):** Both trials are enrolling, and the company has given no readout dates as of 2026-10-28. *(passed 3d ago)*\n\n## What Would Change Our Mind\nThe case breaks if the launch stalls. One sign would be first-quarter TUDRIQEV revenue in the ~2027-02-11 report that is small next to the $450,000 list price and the 200 priority accounts. Another would be a prescriber count that has barely grown from the more than 15 institutions reported on 2026-10-28. Payers narrowing coverage beyond the label would also weaken it.\n\nA second equity raise soon after the August 2026 offering would show cash burn outrunning sales. So would a cut to the \"greater than twelve months\" runway statement. Any FDA action on the accelerated approval, or a disclosed delay or enrollment problem in IGNYTE-3, would undercut the conditional approval the case rests on.\n\nOn price, a daily close below $14.00 would undo most of the rally after the report and mark the launch re-rating as failed.\n\n## Correlation Notes\nReplimune's biggest moves have come from its own regulatory news: the complete response letters, the 2026-07-30 advisory vote and the 2026-08-06 approval. Launch data is now taking over that role. The listed peers make weak comparisons. GMAB and HALO earn revenue from antibody products and royalties, and KNSA is a commercial-stage company in a different disease area, so their quarterly results say little about TUDRIQEV demand. The shares are likely to move with small and mid-cap biotech stocks when investors' appetite for risk shifts. That link would break down if the shares held their gains through a broad biotech sell-off.",
  "first_seen": "2026-10-30",
  "last_analyzed": "2026-10-30T08:14:51+00:00",
  "last_synthesized": "2026-10-30",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}